NCT06775275

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: The First Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Detailed description

Neoadjuvant therapy with experimental treatment followed by surgery.

Conditions

• Resectable Lung Non-Small Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Adebellizumab	adebrelimab
DRUG	Bevacizumab	bevacizumab
DRUG	Platinum-based chemotherapy	paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.

Timeline

• Start date: 2024-09-24
• Primary completion: 2025-12-31
• Completion: 2029-12-31
• First posted: 2025-01-15
• Last updated: 2025-01-15

Locations

1 site across 1 country: China